Help us get Ian critical cancer treatment ❤️

Boy - “What’s the bravest thing you have ever said?”

Horse - “Help…Asking for help isn’t giving up. It’s refusing to give up.”

THE BOY, THE MOLE, THE FOX AND THE HORSE by Charlie Mackesy

Here goes…

Hi,

My name is Jen.

My husband, Ian’s, previously treated bladder cancer has metastasized and spread into his bones. Ian is currently in the 1st quarter of a twelve week chemotherapy regime. His Canadian Medical Oncologist would like to offer him a breakthrough treatment but is unable to due to time required for Canadian government approvals.

In short, our timing is terrible.

On January 5th, 2024 (in 2.5 weeks) we have an evaluation secured in Annapolis, Maryland with the local John Hopkins affiliated Oncology Team to review Ian’s case + lay out the treatment plan ahead. Based on preliminary conversation, he’s a great match.

We’re in a tough position. And we need your help.

We’re working tirelessly to access this breakthrough FDA-approved treatment which is not yet available in Canada (and not covered by insurance) called KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv):

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer:

“These results, showing a 53% reduction in the risk of death for the combination compared to chemotherapy, are striking and may open a new chapter for the treatment of these patients diagnosed with advanced urothelial carcinoma, who face an urgent need for new therapies.” - Dr. Thomas Powles, KEYNOTE-A39 primary investigator, professor of Genitourinary Oncology and director, Barts Cancer Center

“Our goal is to extend the lives of patients with cancer, and these unambiguous survival findings from KEYNOTE-A39 showing that KEYTRUDA plus enfortumab vedotin reduced the risk of death by half when compared to chemotherapy are important to patients and the medical community alike,” - Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories

This new treatment can extend Ian’s quality and length of life, but we need to act swiftly.

Today, we’re reaching out to our community to help us access this treatment.

Each round is $15,000 USD so, with your help, we hope to start the treatment as early as February 5, 2024.

Every dollar counts and we are grateful for any support you can offer.

If you have any questions, please reach out.

In the meantime, thank you.

Jen + Ian

PS: if you want to read more about this treatment, please click here: https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-death-by-more-than-half-versus-chemotherapy-in-patients-with-previously-untreated-locally-advanced-or-metasta/